SCHEMBL5503152

SCHEMBL5503152

COC(=O)c1ccccc1-c1cccc(-c2cnc(N(Cc3ccc(C(F)(F)P(=O)(O)O)c(Br)c3)c3ccc(Cl)c(Cl)c3)o2)c1

nearest known ligand 0.35

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 5/20 0.35
PTPN2 P17706 4/20 0.35
NPC1 O15118 1/20 0.34
ALDH1A1 P00352 1/20 0.34
HPGD P15428 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
FLT1 P17948 1/20 0.34
FLT4 P35916 1/20 0.34
KDR P35968 1/20 0.34
BDKRB1 P46663 1/20 0.33
FAAH O00519 1/20 0.33
PTPN5 P54829 2/20 0.32
PDCD1 Q15116 1/20 0.31
CD274 Q9NZQ7 1/20 0.31
BRS3 P32247 1/20 0.31
ATR Q13535 1/20 0.31
PDK2 Q15119 1/20 0.31
NOTUM Q6P988 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5500754 0.95 PTPN1 (0.37) PTPN1PTPN2ALDH1A1HPGDBDKRB1
SCHEMBL5499218 0.92 PTPN1 (0.37) PTPN1PTPN2NPC1PTPN5
SCHEMBL5502946 0.91 PTPN1 (0.35) PTPN1PTPN2NPC1ALDH1A1HPGD
SCHEMBL5521865 0.90 PTPN1 (0.35) PTPN1PTPN2SMN1; SMN2BDKRB1FAAH
SCHEMBL5505841 0.87 LTB4R2 (0.35) PTPN1PTPN2ALDH1A1HPGDBDKRB1
SCHEMBL5500052 0.87 PTPN1 (0.37) PTPN1PTPN2FAAHPTPN5NOTUM
SCHEMBL5503912 0.87 PTPN1 (0.38) PTPN1PTPN2NPC1PTPN5BRS3
SCHEMBL5503153 0.86 NPC1 (0.34) NPC1ALDH1A1HPGDSMN1; SMN2FLT1
SCHEMBL5500025 0.85 PTPN1 (0.40) PTPN1PTPN2PTPN5
SCHEMBL5502721 0.84 PTPN1 (0.38) PTPN1PTPN2FAAHNOTUM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1786421-A2 OXYGEN/NITROGEN HETEROCYCLE INHIBITORS OF TYROSINE PHOSPHATASES Cengent Therapeutics, Inc. (US) 2007-05-23 EP claimed
US-20060135483-A1 Oxygen/nitrogen heterocycle inhibitors of tyrosine phosphatases METABASIS THERAPEUTICS, INC. 2006-06-22 US claimed
WO-2006017124-A2 OXYGEN/NITROGEN HETEROCYCLE INHIBITORS OF TYROSINE PHOSPHATASES CENGENT THERAPEUTICS, INC. (US) 2006-02-16 WO claimed
EP-1786421-A2 OXYGEN/NITROGEN HETEROCYCLE INHIBITORS OF TYROSINE PHOSPHATASES Cengent Therapeutics, Inc. (US) 2007-05-23 EP disclosed
US-20060135483-A1 Oxygen/nitrogen heterocycle inhibitors of tyrosine phosphatases METABASIS THERAPEUTICS, INC. 2006-06-22 US disclosed
WO-2006017124-A2 OXYGEN/NITROGEN HETEROCYCLE INHIBITORS OF TYROSINE PHOSPHATASES CENGENT THERAPEUTICS, INC. (US) 2006-02-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060135483-A1 Oxygen/nitrogen heterocycle inhibitors of tyrosine phosphatases PTPRO, PTPRG, PTPN1 PTPN1 3/4885PTPN2 24/4885NPC1 3613/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.